# US 10,864,243 B1 · Composition for prostaglandin transporter inhibition and related therapeutic applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,243 B1
- Document ID: US10864243B1
- Status: Granted
- Kind: B1
- Application number: 16/432,950
- Filed: 2019-06-06
- Published: 2020-12-10
- Granted: 2020-12-15
- Earliest claimed: 2019-06-06
- Assignees: Sami Labs Limited
- Applicants: Muhammed Majeed; Kalyanam Nagabhushanam; Sarang Bani; Anjali Pandey
- Inventors: Muhammed Majeed; Kalyanam Nagabhushanam; Sarang Bani; Anjali Pandey
- Web page: https://patentgrep.com/patent/US10864243B1

## CPC

- A61K 36/88: Liliopsida (monocotyledons)
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 36/21: Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
- A61K 36/71: Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K 36/8962: Allium, e.g. garden onion, leek, garlic or chives
- A61P 9/12: Antihypertensives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention discloses a composition comprising Allium sativum extract standardized to contain not less that 0.3% w/w S-allylcysteine, Beta vulgaris extract standardized to contain not less than 2% w/w nitrates, Nigella sativa extract standardized to contain 0.1%-5% w/w thymoquinone, about 0.01%-10% w/w thymohydroquinone, about 20%-95% w/w fatty acids, about 0.001%-3% w/w α-hederin or hederagenin, and Terminalia arjuna extract standardized to contain 3% w/w arjunoglucosides for use a prostaglandin transporter inhibitor. The invention also discloses the use of the aforementioned composition in the therapeutic management of hypertension and cardiovascular complications.

## Claims

### Claim 1

A method for inhibiting prostaglandin transporter in mammalian cells, said method comprising step of bringing into contact mammalian cells expressing prostaglandin transporter with a composition essentially consisting of 30-60% w/w Allium sativum extract is standardized to contain not less than 0.3% S-allylcysteine, 10-30% w/w Beta vulgaris extract standardized to contain not less than 2% nitrates, 5-15% w/w Nigella sativa extract standardized to contain 0.1%-5% w/w thymoquinone, about 0.01%-10% w/w thymohydroquinone, about 20%-95% w/w fatty acids, about 0.001%-3% w/w α-hederin or hederagenin, and 10-30% w/w Terminalia arjuna extract standardized to contain 3% w/w arjunoglucosides.

### Claim 2 (depends on 1)

The method as in claim 1, wherein the prostaglandins are selected from the group comprising prostaglandin E2, prostacyclin, prostaglandin D2, and prostaglandin F2a.

### Claim 3 (depends on 1)

The method as in claim 1, wherein the mammalian cells are human cells.